What Happened

Aspen Neuroscience and Bambusa Therapeutics disclosed their IPO intentions in SEC filings on Friday. Neither company specified share counts or pricing. Aspen's filing follows encouraging phase 1/2a data for its autologous Parkinson's cell therapy sasineprocel, while Bambusa is advancing its bispecific antibody pipeline.

Who Is Affected

Aspen, a San Diego-based biotech with 120 employees, plans to allocate proceeds to its phase 1/2a study and a phase 3 trial of sasineprocel, targeting launch before the earlier study completes. Bambusa, a Boston startup with 30 staff, will fund phase 2b work for BBT001 in atopic dermatitis and continue BBT002 development for COPD. Both companies will also spend on pipeline expansion—Aspen on microglia therapies for leukodystrophies, Bambusa on additional indications.

Market Impact

The IPO filings coincide with TRex Bio ($116.7M) and Retension Pharmaceuticals ($45M) going public, and follow record-breaking 2026 listings like Kailera Therapeutics. This signals a strong biotech funding window, attracting vendors offering clinical, regulatory, and commercialization solutions.

• Aspen's phase 3 launch requires scalable trial infrastructure and regulatory support.
• Bambusa's phase 2b expansion in AD and COPD creates demand for data management and patient recruitment tools.
• Both companies have cash runway ($72.4M and $71.5M respectively) but IPO proceeds will accelerate hiring and vendor selection.

What to Watch

Look for pricing and valuation details in upcoming SEC amendments. Aspen's timeline for phase 3 initiation and Bambusa's next clinical readouts will determine vendor urgency. Aspen's CEO has stated ambition to self-commercialize, which may open opportunities for go-to-market and commercial operations software.

Related coverage

• Anchorage Digital acquires enterprise payouts startup Routable
• TRex Bio prices $117M IPO to support immune drug development
• ADARx scores upsized $446M IPO; City Therapeutics maps out Nasdaq plans
• Inflammation biotech Electra raises $350M in upsized Nasdaq IPO